These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31171642)

  • 21. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
    Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
    Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
    Notaro R; Sica M
    Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile.
    Berger N; Alayi TD; Resuello RRG; Tuplano JV; Reis ES; Lambris JD
    J Med Chem; 2018 Jul; 61(14):6153-6162. PubMed ID: 29920096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design of a modified mouse protein with ligand binding properties of its human analog by molecular dynamics simulations: the case of C3 inhibition by compstatin.
    Tamamis P; Pierou P; Mytidou C; Floudas CA; Morikis D; Archontis G
    Proteins; 2011 Nov; 79(11):3166-79. PubMed ID: 21989937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thermodynamic studies on the interaction of the third complement component and its inhibitor, compstatin.
    Katragadda M; Morikis D; Lambris JD
    J Biol Chem; 2004 Dec; 279(53):54987-95. PubMed ID: 15489226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolution of compstatin family as therapeutic complement inhibitors.
    Huang Y
    Expert Opin Drug Discov; 2018 May; 13(5):435-444. PubMed ID: 29402126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the alternative pathway of human complement in vitro by a natural microbial product, complestatin.
    Kaneko I; Fearon DT; Austen KF
    J Immunol; 1980 Mar; 124(3):1194-8. PubMed ID: 6898640
    [No Abstract]   [Full Text] [Related]  

  • 29. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.
    Lindorfer MA; Pawluczkowycz AW; Peek EM; Hickman K; Taylor RP; Parker CJ
    Blood; 2010 Mar; 115(11):2283-91. PubMed ID: 20068220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of heparin on complement activation and lysis of paroxysmal nocturnal hemoglobinuria (PNH) red cells.
    Logue GL
    Blood; 1977 Aug; 50(2):239-47. PubMed ID: 17439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS.
    Primikyri A; Papanastasiou M; Sarigiannis Y; Koutsogiannaki S; Reis ES; Tuplano JV; Resuello RR; Nilsson B; Ricklin D; Lambris JD
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jan; 1041-1042():19-26. PubMed ID: 27992787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome.
    Arvidsson I; Ståhl AL; Hedström MM; Kristoffersson AC; Rylander C; Westman JS; Storry JR; Olsson ML; Karpman D
    J Immunol; 2015 Mar; 194(5):2309-18. PubMed ID: 25637016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gingival Exudatome Dynamics Implicate Inhibition of the Alternative Complement Pathway in the Protective Action of the C3 Inhibitor Cp40 in Nonhuman Primate Periodontitis.
    Bostanci N; Bao K; Li X; Maekawa T; Grossmann J; Panse C; Briones RA; Resuello RRG; Tuplano JV; Garcia CAG; Reis ES; Lambris JD; Hajishengallis G
    J Proteome Res; 2018 Sep; 17(9):3153-3175. PubMed ID: 30111112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemolysis of normal human erythrocytes by autologous serum complement.
    Kitamura H; Nagano A; Kitano E
    Int Arch Allergy Immunol; 1993; 100(3):209-14. PubMed ID: 8453307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous and standard immune serum globulin preparations interfere with uptake of 125I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activity.
    Berger M; Rosenkranz P; Brown CY
    Clin Immunol Immunopathol; 1985 Feb; 34(2):227-36. PubMed ID: 4038476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts.
    Fiane AE; Mollnes TE; Videm V; Hovig T; Høgåsen K; Mellbye OJ; Spruce L; Moore WT; Sahu A; Lambris JD
    Xenotransplantation; 1999 Feb; 6(1):52-65. PubMed ID: 10355733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding and activation of C4 and C3 on the red cell surface by non-complement enzymes.
    Kirschfink M; Borsos T
    Mol Immunol; 1988 May; 25(5):505-12. PubMed ID: 3412332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons.
    Soulika AM; Khan MM; Hattori T; Bowen FW; Richardson BA; Hack CE; Sahu A; Edmunds LH; Lambris JD
    Clin Immunol; 2000 Sep; 96(3):212-21. PubMed ID: 10964539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition.
    Janssen BJ; Halff EF; Lambris JD; Gros P
    J Biol Chem; 2007 Oct; 282(40):29241-7. PubMed ID: 17684013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence suggesting the occurrence of C3-independent intravascular immune hemolysis. Reactive hemolysis in vivo.
    Salama A; Bhakdi S; Mueller-Eckhardt C
    Transfusion; 1987; 27(1):49-53. PubMed ID: 3810824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.